anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: To use ultra-widefield swept-source optical coherence tomography angiography (UWF SS-OCTA) to evaluate the choroidal features of neovascular age-related macular degeneration (nAMD) and type 1 macular neovascularization (MNV) attributable to central serous chorioretinopathy (CSC).
METHOD: A cross-sectional research was carried out to examine patients with type 1 MNV due to CSC (50 eyes) and nAMD (98 eyes) utilizing UWF SS-OCTA examinations. The scan procedure covered a vertical 20 mm × horizontal 24 mm region with 9 subfields. A typical set of 68 healthy eyes was used for comparison. The effects of different diagnoses on choroidal parameters were assessed using covariance tests, using gender and age as variables.
RESULTS: The research showed that all choroidal characteristics were age-related (all p < 0.05). The calculated marginal averages of choroidal thickness (ChT) and choroidal volume (CV) in the central area were substantially lower in the nAMD group than in the CSC group and the normal group after age differences were taken into account (all p < 0.05). In both the superotemporal and temporal areas, the CSC group had a greater choroidal vascular index (CVI) compared to the nAMD group (p < 0.05). Additionally, the CSC group had a greater temporal area choriocapillaris density (CCD) than the nAMD group (p < 0.05).
CONCLUSION: At the choroidal level, type 1 MNV due to CSC and nAMD may be distinguished by UWF SS-OCTA. Compared to the nAMD affected eyes, the CSC affected eyes had increased ChT, CV, CVI, and CCD in several areas. The two diseases could be distinguished based on ChT and CV.
Antenna in the microwave ablation device was percutaneously inserted into the tumor and placed at designated place under US guidance. For tumors less than 1.5 cm, one antenna was inserted and for tumors measuring 1.5 cm or greater, two antennae were inserted in parallel with an inter-antenna distance of 1.0-2.5 cm, which were used simultaneously during MWA to obtain larger ablation zone. A 20G thermocouple was inserted about 0.5-1 cm away from the tumor for real-time temperature monitoring during MWA. MW emission didn't stop until the heat-generated hyperechoic water vapor completely encompassed the entire tumor and the measured temperature reached 60°C or remained above 54°C for at least three minutes.
The present invention relates to a method for producing a cosmetic composition comprising an illite extract as an active ingredient. Specifically, the method comprises: a first step of preparing salt-removed deep sea water; a second step of mixing the purified deep sea water and illite powder in a sealed container; a third step of performing vaporizing by pressurizing and heating the container containing a mixture; a fourth step of condensing the water vapor discharged through the pipe connected to the sealed container; and a fifth step of extracting plant extracts by hot water extraction of two or more plants of angelica, eoseongcho, trifolieae, baeknyeoncho, lavender, spinach, apricot seed, wormwood, and paprika using the purified deep sea water. Accordingly, various minerals including silicate, calcium salt, etc. are abundantly contained, and it is possible to prepare a cosmetic composition capable of adjusting the pH suitable for the skin type. In addition, the supply can be stably maintained by using deep sea water instead of using limited groundwater. The present invention has the advantage of being rich in oxygen and improving moisture and elasticity.
BACKGROUND: Pinworm, Enterobius vermicularis, is a common parasitic illness, particularly among children in Palestine. On rare occasions, it can cause serious consequences such as acute appendicitis, which can still present a challenging diagnosis especially in children.
CASE PRESENTATION: This report describes two cases (a 9 year old male and a 11 year old female, both Palestinian children from Hebron district) of acute appendicitis referred to Queen Alia Hebron Governmental Hospital in Palestine. The clinical examination revealed a lower abdominal pain, and they were diagnosed with appendicitis. The pathological examination after appendectomy showed the presence of eggs and pinworms. Anthelminthic medication was provided, and they were followed up for 6 weeks after the operation without any incidents.
CONCLUSION: These cases highlight the importance of considering Enterobius vermicularis infestation in children with abdominal pain, as the parasites can mimic appendicitis. Prompt recognition and cautious laparoscopic appendectomy are crucial to prevent unnecessary surgery and peritoneal contamination, with the infestation being easily treatable with anthelmintic medication.
Method and system for remote medical information exchange are disclosed. The system for information exchange comprises a mirror configured to capture the facial information of a user and display inference information about the user. The system can comprise an image capture module configured to capture the facial information of the user while the user is looking into the mirror. The system can include a displaying module, coupled to a display integrated into the mirror and configured to cause display of inference information about the user. An on-mirror computation device, coupled in communication with the image capture module and the displaying module, is configured to receive and process facial information of the user and produce inference information about the user. The on-mirror computation device can comprise one or more artificial intelligence modules.
PURPOSE: A method of making a hair growth promoting agent by using an ethanol extract of Pulsatilla cernua, a water extract of Allium sativum L. an ethanol extract of Scutellaria baicalensis and a water extract of Scutellaria baicalensis is provided. The product kills demodex folliculorum on the scalp to prevent hair loss and promote the growth of hair and causes no adverse effects. CONSTITUTION: The hair growth promoting agent contains the same weight ratio of an ethanol extract of Pulsatilla cernua, a water extract of Allium sativum L. an ethanol extract of Scutellaria baicalensis and a water extract of Scutellaria baicalensis. To make the hair growth promoting agent, a mixture of Pulsatilla cernua and Scutellaria baicalensis is soaked with purified water in a weight ratio of 1:9 for 60 days. A mixture of Allium sativum L. and Scutellaria baicalensis is heated with purified water in a weight ratio of 1:15 at 100deg.C for 2hr. The hair growth promoting agent is added to a shampoo for preventing hair loss or promoting hair growth in an amount of 1%.
BACKGROUND: Ruptured atherosclerotic plaques often precipitate severe ischemic events, such as stroke and myocardial infarction. Unraveling the intricate molecular mechanisms governing vascular smooth muscle cell (VSMC) behavior in plaque stabilization remains a formidable challenge.
METHODS: In this study, we leveraged single-cell and transcriptomic datasets from atherosclerotic plaques retrieved from the gene expression omnibus (GEO) database. Employing a combination of single-cell population differential analysis, weighted gene co-expression network analysis (WGCNA), and transcriptome differential analysis techniques, we identified specific genes steering the transformation of VSMCs in atherosclerotic plaques. Diagnostic models were developed and validated through gene intersection, utilizing the least absolute shrinkage and selection operator (LASSO) and random forest (RF) methods. Nomograms for plaque assessment were constructed. Tissue localization and expression validation were performed on specimens from animal models, utilizing immunofluorescence co-localization, western blot, and reverse-transcription quantitative-polymerase chain reaction (RT-qPCR). Various online databases were harnessed to predict transcription factors (TFs) and their interacting compounds, with determination of the cell-specific localization of TF expression using single-cell data.
RESULTS: Following rigorous quality control procedures, we obtained a total of 40,953 cells, with 6,261 representing VSMCs. The VSMC population was subsequently clustered into 5 distinct subpopulations. Analyzing inter-subpopulation cellular communication, we focused on the SMC2 and SMC5 subpopulations. Single-cell subpopulation and WGCNA analyses revealed significant module enrichments, notably in collagen-containing extracellular matrix and cell-substrate junctions. Insulin-like growth factor binding protein 4 (IGFBP4), apolipoprotein E (APOE), and cathepsin C (CTSC) were identified as potential diagnostic markers for early and advanced plaques. Notably, gene expression pattern analysis suggested that IGFBP4 might serve as a protective gene, a hypothesis validated through tissue localization and expression analysis. Finally, we predicted TFs capable of binding to IGFBP4, with Krüppel-like family 15 (KLF15) emerging as a prominent candidate showing relative specificity within smooth muscle cells. Predictions about compounds associated with affecting KLF15 expression were also made.
CONCLUSION: Our study established a plaque diagnostic and assessment model and analyzed the molecular interaction mechanisms of smooth muscle cells within plaques. Further analysis revealed that the transcription factor KLF15 may regulate the biological behaviors of smooth muscle cells through the KLF15/IGFBP4 axis, thereby influencing the stability of advanced plaques via modulation of the PI3K-AKT signaling pathway. This could potentially serve as a target for plaque stability assessment and therapy, thus driving advancements in the management and treatment of atherosclerotic plaques.
Knee pain athletes were assessed by The International Knee Documentation Committee (IKDC) 2000 Subjective Knee evaluation form and were assigned into ISOM group. ISOM group participants were involved in isometric strengthTraining at angle of 30°,45°,60° of knee flexion for 5 maximum contraction for both hamstring and quadriceps. 10 sessions were given on alternate day basis by using Biodex Isokinetic system.
The efficacy of XANAX XR in the treatment of panic disorder in adults was established in two 6-week, flexible-dose, placebo-controlled studies in adult patients meeting DSM-III criteria for panic disorder. In these studies, patients were treated with XANAX XR in a dose range of 1 mg to 10 mg once per day. The effectiveness of XANAX XR was assessed on the basis of changes in various measures of panic attack frequency, on various measures of the Clinical Global Impression, and on the Overall Phobia Scale. In all, there were 7 primary efficacy measures in these studies, and XANAX XR was superior to placebo on all 7 outcomes in both studies. The mean dose of XANAX XR at the last treatment visit was 4.2 mg per day in the first study and 4.6 mg per day in the second.

In addition, there were two 8-week, fixed-dose, placebo-controlled studies of XANAX XR in adult patients with panic disorder, involving fixed XANAX XR doses of 4 mg and 6 mg once per day that did not show a benefit for either dose of XANAX XR.

Analyses of the relationship between treatment outcome and gender did not suggest any differential responsiveness on the basis of gender.
Methotrexate can cause fetal death or teratogenic effects when administered to a pregnant woman. Methotrexate is contraindicated in pregnant women with psoriasis or rheumatoid arthritis and should be used in the treatment of neoplastic diseases only when the potential benefit outweighs the risk to the fetus. Women of childbearing potential should not be started on methotrexate until pregnancy is excluded and should be fully counseled on the serious risk to the fetus (see PRECAUTIONS) should they become pregnant while undergoing treatment. Pregnancy should be avoided if either partner is receiving methotrexate; during and for a minimum of three months after therapy for male patients, and during and for at least one ovulatory cycle after therapy for female patients. (see Boxed WARNINGS).

Because of the potential for serious adverse reactions from methotrexate in breast fed infants, it is contraindicated in nursing mothers.

Patients with psoriasis or rheumatoid arthritis with alcoholism, alcoholic liver disease or other chronic liver disease should not receive methotrexate. 

Patients with psoriasis or rheumatoid arthritis who have overt or laboratory evidence of immunodeficiency syndromes should not receive methotrexate.

Patients with psoriasis or rheumatoid arthritis who have preexisting blood dyscrasias, such as bone marrow hypoplasia, leukopenia, thrombocytopenia, or significant anemia, should not receive methotrexate.

Patients with a known hypersensitivity to methotrexate should not receive the drug.
BACKGROUND: The COMPASS trial demonstrated that in patients with atherosclerotic diseases, low-dose rivaroxaban and aspirin provides greater protection against subsequent major adverse cardiovascular events (MACEs) than mono-antiplatelet therapy (MAPT) alone. Drug acceptance and adherence maximizes this benefit. We have assessed drug acceptance and adherence to the COMPASS drug regime in patients following carotid endarterectomy (CEA) for symptomatic carotid artery stenosis.
METHODS: Following CEA, the views of 63 patients on the COMPASS drug regime were assessed using the Beliefs about Medicine Questionnaire and drug adherence was determined using the Sidorkiewicz scoring system. These views were compared with those of 54 patients on MAPT. Side effects (bleeding and drug reactions) and new MACE were recorded.
RESULTS: Post-CEA patients on the COMPASS drug regimen had strong positive views on the necessity to take these drugs (necessity scale 19.6 ± 3.6). Although there were some concerns about the COMPASS drug regimen, these were not strongly held (concern cscale 11.8 ± 4.9) and the necessity-concerns differential was positive (7.8 ± 6.2). The Drug Adherence Score was "High" to "Good" (level of drug adherence 1.7 ± 1.0). The Beliefs about Medicine Questionnaire scales and Drug Adherence Score of post-CEA patients on the COMPASS drug regimen were similar to those on MAPT. The incidence of post-CEA MACE and side effects were similar for those on the COMPASS drug regimen and MAPT.
CONCLUSIONS: Post-CEA patients on the COMPASS drug regimen had positive views on taking the drugs and drug adherence was high. We did not identify any patient-related barriers to the use of the COMPASS drug regimen to further reduce cardiovascular events.
The present invention relates to a chamaecyparis obtusa oil extracting device and a chamaecyparis obtusa oil extracting method using the same. The chamaecyparis obtusa oil extracting device comprises: a raw material container, a thermometer, a steam generating device, a first cooling device, a second cooling device, an oil separating device, a first channel, a second channel, a third channel, and a fourth channel. The raw material container prepares a space for loading crushed chamaecyparis obtusa woods. The thermometer is provided in an upper end of the raw material container and senses a temperature of the raw material container. The steam generating device supplies steam to a lower side of the raw material container. The first cooling device includes: a plurality of first steam engines which condenses the steam generated in the raw material container, and a first cooling unit which is provided around a first steam engine. The second cooling device includes: a spiral second steam engine which condenses first condensate generated by the first cooling device again; a second cooling unit which is provided around the second steam engine; and a supplying unit which supplies a liquid or gas filled in the cooling unit to a lower end of one side. The oil separating device separates second condensate generated in the second cooling device into water and oil. The first channel connects the raw material container and the steam generating device, and includes a first valve in one side. The second channel connects the raw material container and the first steam engines, and includes a second valve in one side. The third channel connects the first steam engine and the second steam engine to the inside, and connects the first cooling unit and the second cooling unit to the outside. The fourth channel connects the second cooling device and the oil separating device. When the temperature of the raw material container reaches 110-115°C, the second valve is opened. The present invention can increase productivity of chamaecyparis obtusa oil.
The participants of the COGNITIVE group performed cognitive training during 12 sessions during the 3 months of hypocaloric treatment. The training was carried out with the PC game Brain Exercise TM (Bandai Namco Games Ltd.). The participants made a total of 12 practice exercises, which implies approximately 30 minutes of duration per session.
PURPOSE OF REVIEW: Lung transplant outcomes are impacted by multiple modifiable risk factors. Candidate deterioration on the wait list remains problematic. Innovative technology and strategies to identify and impact pretransplant morbidity have improved short- and long-term outcomes. We focus our review on recent advances in pretransplant recipient assessment and optimization.
RECENT FINDINGS: Advancements in recipient management have focused on risk factor identification for adverse outcomes and the development of a lung transplant specific frailty assessment. Early surgical correction of gastroesophageal reflux disease (GERD), including the use of partial fundoplication in the setting of esophageal dysmotility, leads to improvements in graft function/longevity. New evidence supports expanding criteria for extracorporeal life support as a bridge to transplant.
SUMMARY: Candidate optimization requires early intervention to limit functional deterioration potentially contributing to adverse outcomes. Frailty can be identified with a transplant specific frailty assessment, and positively impacted with dedicated rehabilitation. Pretransplant frailty is reversible following transplant and should be considered in the context of overall fitness at the time of candidate selection. Invasive support modes including extracorporeal membrane oxygenation (ECMO) are appropriate to preserve strength and mobility, with awake, ambulatory ECMO preferred. The deleterious effect of GERD on graft function can be managed with early fundoplication over medical management alone.
Obese individuals will a Very Low Calorie Diet (VLCD) using the HMR meal replacement (Health Management Resources, Boston, MA) for 3-6 months until individually targeted weight loss determined by a clinician is reached. Typically, individuals consume 850-1000 kilocalories per day.
Enrolled subjects will receive single oral dose of 4 FDCs i.e., FDC1, FDC2, FDC3 and FDC4, and reference formulations of the 2 monotherapy components taken concurrently in the fasted state. The FDC and reference formulations contains 10 mg ambrisentan and 40 mg tadalafil. Each dosing period will be separated by 7 days wash out period.
BACKGROUND: The roles of Caveolin-1 (Cav-1) and the Wnt/β-catenin signaling pathways in cerebral ischemia-reperfusion (I/R) injury are well established. The translocation of β-catenin into the nucleus is critical for regulating neuronal apoptosis, repair, and neurogenesis within the ischemic brain. It has been reported that the scaffold domain of Caveolin-1 (Cav-1) (residues 95-98) interacts with β-catenin (residues 330-337). However, the specific contribution of the Cav-1/β-catenin complex to I/R injury remains unknown.
METHODS AND RESULTS: To investigate the mechanism underlying the involvement of the Cav-1/β-catenin complex in the subcellular translocation of β-catenin and its subsequent effects on cerebral I/R injury, we treated ischemic brains with ASON (Cav-1 antisense oligodeoxynucleotides) or FTVT (a competitive peptide antagonist of the Cav-1 and β-catenin interaction). Our study demonstrated that the binding of Cav-1 to β-catenin following I/R injury prevented the nuclear accumulation of β-catenin. Treatment with ASON or FTVT after I/R injury significantly increased the levels of nuclear β-catenin. Furthermore, ASON reduced the phosphorylation of β-catenin at Ser33, Ser37, and Thr41, which contributes to its proteasomal degradation, while FTVT increased phosphorylation at Tyr333, which is associated with its nuclear translocation.
CONCLUSIONS: The above results indicate that the formation of the Cav-1/β-catenin complex anchors β-catenin in the cytoplasm following I/R injury. Additionally, both ASON and FTVT treatments attenuated neuronal death in ischemic brains. Our study suggests that targeting the interaction between Cav-1 and β-catenin serve as a novel therapeutic strategy to protect against neuronal damage during cerebral injury.
The invention relates to a new application of Annexin-A1 short peptide (ANXA 1 sp) in resisting craniocerebral injury. The annex tripeptide can obviously improve the nerve function of mice after craniocerebral injury and slow down the injury of motor function under the condition of therapeutic administration. The applicant of the present invention administers different concentrations of annexin tripeptides therapeutically to adult mice simulating craniocerebral injury and performs neurological and motor function assessment on the mice. It is found that therapeutic administration of certain concentration of annexin can obviously reduce the nerve function score of mice after craniocerebral injury and improve the motor function of the mice. By the method, the annexin tripeptide medicament is therapeutically administered, so that the nerve function of mice after craniocerebral injury can be obviously improved, the motor function injury is slowed down, and powerful evidence is provided for human experiments. If the method can be popularized to human body application, the method has better economic benefit and social benefit.
INTRODUCTION: Concentrated Growth Factor (CGF), rich in CD34 + stem cells, is widely used in treatments for androgenetic alopecia and skin rejuvenation due to its immune-modulating properties. Psoriasis, a chronic inflammatory skin condition, presents significant treatment challenges, particularly for patients who cannot use biologics due to conditions such as cancer and lesions resistant to treatments. The potential of CGF in treating psoriasis is promising, given its broad immunoregulatory effects which confirmed in our previous androgenetic alopecia work.
METHODS: We evaluated the impact of CGF on IL-17 levels in two contexts: patients treated for androgenetic alopecia and a psoriasis mouse model. Twelve patients received three monthly injections of CGF, with serum IL-17 levels measured before and after treatment. In the psoriasis mouse model, groups were treated with CGF, and outcomes were assessed using the Psoriasis Area and Severity Index (PASI), skin barrier scores, histological analysis, and RNA sequencing. Additionally, in vitro experiments applied CD34 + cells from CGF to keratinocytes to measure levels of TNF-α, IFN-γ, IL-23, and IL-17.
RESULTS: In patients with androgenetic alopecia, three monthly CGF injections resulted in significantly reduced serum IL-17 levels. In the psoriatic mouse model, CGF-treated groups exhibited lower PASI scores and improved skin barrier scores compared to controls. Histological analysis revealed enhanced skin characteristics, while RNA sequencing demonstrated downregulated IL-17 and upregulated CD34 expression, as well as improved expression of barrier-related genes. In vitro, the application of CD34 + cells from CGF to keratinocytes led to a significant reduction in TNF-α, IFN-γ, IL-23, and IL-17 levels, indicating strong anti-inflammatory effects. A clinical case of a psoriasis patient unresponsive to IL-23 therapy (Guselkumab) showed significant improvement following CGF treatment.
CONCLUSION: These findings indicate that CGF could serve as an effective and versatile treatment for psoriasis, especially for patients who have already undergone biologic therapies but continue to experience resistant lesions.